Biotech · Public company · San Francisco, CA, US
Olema Pharmaceuticals, Inc.
Ticker OLMA · SEC CIK 0001750284
Track this companyFree. Adds Olema Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials54 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline15
- AnastrozolePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ExemestanePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LetrozolePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PalazestrantPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RibociclibPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- OP-1250Phase 2 · Hormone Receptor Positive Breast CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- AlpelisibPhase 1 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- AtirmociclibPhase 1 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- EverolimusPhase 1 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 1 · Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)ClinicalTrials.gov · fetched Nov 12, 2026
- OP-3136Phase 1 · Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)ClinicalTrials.gov · fetched Nov 12, 2026
- PalazestrantPhase 1 · Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)ClinicalTrials.gov · fetched Nov 12, 2026
- PalazestrantPhase 1 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RibociclibPhase 1 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPHASE3 · RECRUITING · started Nov 3, 2025ClinicalTrials.gov NCT07085767 · fetched Nov 12, 2026
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPHASE1 · RECRUITING · started Dec 16, 2024ClinicalTrials.gov NCT06784193 · fetched Nov 12, 2026
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 16, 2023ClinicalTrials.gov NCT06016738 · fetched Nov 12, 2026
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 31, 2022ClinicalTrials.gov NCT05508906 · fetched Nov 12, 2026
- A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerPHASE1_PHASE2 · COMPLETED · started Aug 13, 2020ClinicalTrials.gov NCT04505826 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 21, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 1, 2026 · fetched Nov 12, 2026